Medical Care Technologies Inc. develops and commercializes artificial intelligence applications across consumer software, imaging analysis, healthcare-oriented pre-screening and collectibles authentication. News about MDCE centers on its AI technology stack, including Snapshot Recipes, a mobile recipe application with AI-generated food and beverage content, and Real Game Used, a subsidiary developing a patent-pending AI authentication platform for sports memorabilia.
Company updates also cover AI imaging initiatives for dermatological analysis, wellness monitoring, product verification and automated quality control, as well as capital and asset-monetization activity through Infinite Auctions. Recurring announcements describe product redesigns, commercialization pathways, subsidiary activity, mobile-app user growth initiatives, and enterprise API or visual analytics use cases.
Medical Care Technologies (MDCE) published internal technical evaluation results for its wound-monitoring application, which remains in development and continuous training.
Testing used controlled sequential smartphone captures. 84% met the internal image-usability threshold and advanced to comparison. On usable sequences, wound-boundary stability was 87%, with reduced drift versus the prior internal cycle when lighting and distance remained within the usable range. Alignment completed on 91% of multi-frame usable sequences for visual review over time.
These are technical workflow results, not clinical study results or evidence of clinical efficacy. The application has not received regulatory clearance and is not intended to diagnose or treat disease.
Medical Care Technologies (MDCE) continues accepting human-submitted images for internal testing of its Melanoma Scan Beta imaging and monitoring application.
Updated evaluation results are expected on the corporate website in the coming weeks. The September 29 first-pass results indicated that user photographs could pass through image-quality scoring, body-map registration and comparison over time. Additional submissions are intended to broaden testing across real-world photographic conditions.
The application remains in beta development and has not received regulatory clearance. Participation is internal technical evaluation, not a clinical efficacy trial or diagnosis program; the application is not a substitute for professional medical evaluation.
Medical Care Technologies (MDCE) plans to publish updated internal testing results for its wound-monitoring application on October 12, 2026.
The corporate website update is expected to cover image-quality scoring, wound-boundary identification and comparisons of images taken over time. The models remain in continuous training following the move into structured internal evaluation announced on September 28. The posting is intended as a technical progress report, not a product launch or clinical study result. The application remains in development and has not received regulatory clearance.
Medical Care Technologies (MDCE) is advancing negotiations through Infinite Auctions to supply New York Knicks game-worn memorabilia for potential Topps card products.
The talks follow an initial memorabilia sale to Topps, whose completion was announced in September. Real Game Used, another wholly owned subsidiary, provided photo-match authentication to document game use. The current discussions concern championship-era Knicks material following the team's 2026 NBA title. No Knicks supply agreement has been signed; terms, item selection and authentication scope remain under negotiation. The update does not constitute a binding purchase order or guaranteed volume commitment.
Medical Care Technologies (MDCE) completed another round of Snapshot Recipes optimizations and is rolling out new promotional campaigns this week.
The company says the update is designed to make its consumer AI cooking app faster and smoother. Campaigns focus on generating recipes from grocery or meal photos, with App Store and Google Play download prompts. No updated user counts or rankings were provided, and the announcement does not forecast downloads, revenue or user growth. Medical Care Technologies was debt free as of September 23, 2026.
Medical Care Technologies (OTCID:MDCE) detailed StrainScan Pro's agricultural configuration and demonstration activity as it looks toward its first enterprise clients.
The platform is live and is designed to analyze crop imagery for visible signs of disease, ripeness, pest damage, nutrient stress and yield irregularity. The field workflow compares images with earlier captures and routes alerts based on operator-defined thresholds. This announcement describes demonstration activity, not a signed customer contract or revenue forecast. StrainScan Pro is not a medical device.
Medical Care Technologies (MDCE) reported first-pass results from volunteer-image testing of its Melanoma Scan Beta workflow.
A substantial portion of the initial images met internal thresholds for focus, framing and visible-area isolation; images below those thresholds were excluded from mapping and comparison. Usable images were assigned to mapped body regions. Where more than one usable image covered the same mapped area, the platform completed side-by-side review. These are workflow findings, not clinical validation, performance benchmarks or diagnostic accuracy results. The company plans further evaluation passes as more volunteer images are collected.
Medical Care Technologies (MDCE) has moved its AI-assisted wound-monitoring application into structured internal testing of sequential wound images.
The tool is intended to let users capture smartphone photos of the same wound over time and review visible changes. Evaluation covers photo consistency, wound-boundary visualization, comparisons across sessions and whether the capture-and-review process can be repeated outside a clinic. The application remains in development. No product launch has been announced, and it has not received regulatory clearance.
The work uses the AI vision foundation also being tested in Melanoma Scan Beta, whose first volunteer-submitted image datasets are under internal review. The company was debt free as of September 23, 2026.
Medical Care Technologies (MDCE) reported it was debt free as of September 23, 2026, while continuing software development and demonstrations.
Its Melanoma Scan Beta has received its first human volunteer image datasets, which are under internal review. The platform remains in beta, has not received regulatory clearance and is not intended to diagnose or treat a medical condition. The wound-monitoring application remains in development. StrainScan Pro continues in enterprise demonstrations for agricultural and foodservice applications.
Subsidiaries Infinite Auctions and Real Game Used continue memorabilia transactions and photo-match authentication, including a recently completed first Fanatics / Topps supply-and-authentication cycle.
Medical Care Technologies (MDCE) has begun internal review of its first volunteer-submitted image datasets for the MDCE Melanoma Scan Beta application as part of its multi-phase testing protocol.
These initial human datasets follow the September 16 intake milestone and introduce real-world user conditions such as lighting, device type, distance, angle, image quality, and skin appearance beyond public dermatology archives. The review phase is testing three core functions: image intake through the beta workflow, placement on an interactive body map, and change-over-time visual comparison of mapped skin areas. Melanoma Scan Beta remains in beta development, has no regulatory clearance, and is not intended for diagnosis or treatment or as a substitute for professional medical evaluation.